Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Oldesloe – page 49

1 417 clinical trials in Bad Oldesloe, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Oldesloe at a glance
1 417
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 417 trials in Bad Oldesloe

Open in trial search

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Not yet recruiting

Study on the Effects and Safety of Cemiplimab and BNT116 in Adults with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Cilcare

Renal disorder

Not yet recruiting

Study of Surovatamig and Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19 in Adults with Antibody-Mediated Kidney Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Miglustat oral solution safety and efficacy study in pediatric patients with CLN3 disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Miglustat
  • Sponsor:Theranexus

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Oldesloe

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on anticoagulation therapy in patients with irregular heartbeat who have undergone coronary stent placement. The research evaluates new approaches to prevent blood clot formation while maintaining patient safety.

  • Atrial Fibrillation Management
  • Post-PCI Treatment Strategies
  • Bleeding Risk Assessment

These trials aim to optimize antithrombotic treatment regimens following coronary interventions.

02 Coronary Interventions

Advanced research investigating treatment strategies for patients with ST-Elevated Myocardial Infarction, comparing different approaches to antiplatelet therapy and revascularization techniques.

  • Prasugrel-based Therapy
  • OCT-guided Procedures
  • Stent Optimization

The studies focus on improving outcomes in heart attack patients through innovative imaging and medication protocols.

03 Interventional Cardiology

Comprehensive evaluation of dual antiplatelet therapy protocols and their optimization in patients undergoing coronary interventions, with special attention to timing and duration of treatment.

  • Revascularization Techniques
  • Medication Protocols
  • Patient Safety Outcomes

These studies aim to establish more effective and safer treatment strategies for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.